Genomic data for these studies is available through AMP-PD.
Specimen Table
| Cohort | Population | Genomic DNA | RNA | Plasma | Serum | CSF | Whole Blood | Urine | Saliva (Passive Drool) | Whole Blood Pellet |
|---|---|---|---|---|---|---|---|---|---|---|
| PDBP | PD and PD-like Cases, Controls | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ||
| BioFIND | Moderately Advanced PD, Controls | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ||
| STEADYPD3 | Early PD | ✔ | ✔ | |||||||
| SUREPD3 | Early PD | ✔ | ✔ |
Study Details
Parkinson’s Disease Biomarkers Program (PDBP)
- Study Subjects
Subjects are recruited and evaluated at one of 9 PDBP-funded research studies, located throughout the United States. Study subjects include individuals at various stages of Parkinson disease (PD) as well as controls. Basic study population information can be seen here.
- Available Data
PDBP-funded research studies collect a minimal dataset for each evaluated subject. More information on study data is available here.
- Available Biospecimens
DNA and RNA from blood, plasma, serum, whole blood, and CSF are available for request.
- Specimen Catalog
The catalog for PDBP is hosted by the NINDS Data Management Resource (DMR). Use the link below to access the PDBP catalog to view available specimens along with a minimal clinical data set.
The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP) was developed to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's disease. PDBP was established to promote the discovery of biomarker candidates for early detection and measurement of disease progression.
BioFIND
- Study Subjects
126 well-defined, moderately advanced PD patients and 106 healthy controls
- Available Data
Demographic information, neurological history, medication history, MoCA (Montreal Cognitive Assessment), ADL (Activities of Daily Living), MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease Rating Scale), Hoehn and Yahr Stage, and Sleep/RBD (REM Sleep Behavior Disorder) questionnaire. All data are de-identified to protect patient privacy.
- Available Biospecimens
DNA and RNA from blood, plasma, whole blood pellet, CSF, urine and saliva.
- Specimen Catalog
The catalog for BioFIND is hosted by LONI. Use the link below to access the BioFIND catalog to view available specimens along with a minimal clinical data set.
BioFIND is a cross-sectional clinical study, designed to discover and verify biomarkers of Parkinson's disease. It is sponsored by the Michael J. Fox Foundation with support from the National Institute of Neurological Disorders and Stroke. Investigators who request access to the BioFIND resource will be required to comply with the BioFIND Biospecimens User Agreement and/or the Data Use Agreement and to adhere to the Publication Policy.
STEADY-PDIII
- Study Subjects
366 subjects with early idiopathic PD not requiring dopaminergic therapy were enrolled into the study. De-identified measures of neurological function, severity of PD, cognition, and mood are available for study subjects. There are no matching controls as part of this cohort.
- Available Data
Measures of neurological function, severity of PD, cognition, and mood. All data are de-identified to protect patient privacy.
- Available Biospecimens
DNA from blood and plasma
**Baseline samples were collected on
- Specimen Catalog
The catalog for STEADYPD3 is hosted by the NINDS Data Management Resource (DMR) as part of their PDBP catalog. Use the link below to access the PDBP catalog to view available specimens along with a minimal clinical data set.
The STEADY-PD III study was conducted to establish efficacy of isradipine to slow progression of Parkinson's disease (PD) disability as determined by the change in the total (Part I-III) Unified Parkinson Disease Rating Scale (UPDRS) score.
SURE-PDIII
- Study Subjects
The Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3) was intended to be a two year, placebo-controlled, double-blinded trial of oral inosine treatment in individuals with PD. This trial was concluded early due to lack of effect of the treatment on the primary outcome measure of disease progression. Specimens were collected for plasma over several visits: at baseline, after up to 24 of treatment, and 3 months (of washout) later. There are a total of 287 subjects available; 192 have both plasma and DNA available, with the remaining 95 subjects having only plasma.
- Available Data
Measures of neurological function, severity of PD, cognition, and mood. All data are de-identified to protect patient privacy.
- Available Biospecimens
DNA from blood and plasma.
- Specimen Catalog
The catalog for SUREPD3 is hosted by the NINDS Data Management Resource (DMR) as part of their PDBP catalog. Use the link below to access the PDBP catalog to view available specimens along with a minimal clinical data set.
SURE-PD3 was a Phase III clinical trial to examine if increasing levels of Urate decelerate disease progression in recently-diagnosed individuals who have not begun dopaminergic therapy. Investigators who request access to this resource will be required to comply with the BioSEND Biospecimens User Agreement and/or the Data Use Agreement and to adhere to the Publication Policy.